2-羟基-4-溴-6-硝基甲苯 | 864550-41-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-羟基-4-溴-6-硝基甲苯
• 英文名称: 5-bromo-2-methyl-3-nitrophenol
• 英文别名: 5-bromo-2-methyl-3-nitro-phenol
• CAS: 864550-41-4
• 化学式: C₇H₆BrNO₃
• mdl: MFCD07781363
• 分子量: 232.034
• InChiKey: KDUWLYPHIKTHCV-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C
• 沸点：
  312.1±42.0 °C(Predicted)
• 密度：
  1.755±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-羟基-4-溴-6-硝基甲苯 在 四氢吡咯 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.25h， 生成 6-溴-4-甲氧基-1H-吲哚
  参考文献：
  名称：

  A Concise Total Synthesis of Breitfussin A and B

  摘要：

  The first total synthesis of breitfussin A and B is described. The approach features two palladium-catalyzed cross-couplings installing the indole and pyrrole onto the oxazole core and selective lithiation/iodination of a common indole-oxazole fragment providing 2,4-diiodinated or 2-iodinated oxazoles as potential precursors for breitfussin A and B, respectively. An unexpected acid promoted deiodination was utilized in the synthesis of breitfussin B. Comparison of the synthetic material with previously reported spectral data of isolated breitfussin A and B verified the structure of the breitfussin framework.

  DOI：

  10.1021/ol503348n
• 作为产物：
  描述：

  2,6-二硝基甲苯 在 吡啶 、 ammonium sulfide 、 1,3-二溴-5,5-二甲基海因 、 硫酸 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 5.0h， 生成 2-羟基-4-溴-6-硝基甲苯
  参考文献：
  名称：

  A Concise Total Synthesis of Breitfussin A and B

  摘要：

  The first total synthesis of breitfussin A and B is described. The approach features two palladium-catalyzed cross-couplings installing the indole and pyrrole onto the oxazole core and selective lithiation/iodination of a common indole-oxazole fragment providing 2,4-diiodinated or 2-iodinated oxazoles as potential precursors for breitfussin A and B, respectively. An unexpected acid promoted deiodination was utilized in the synthesis of breitfussin B. Comparison of the synthetic material with previously reported spectral data of isolated breitfussin A and B verified the structure of the breitfussin framework.

  DOI：

  10.1021/ol503348n

文献信息

• Pyranouidole Derivatives and the Use Thereof for the Treatment of Hepatitis C Virus Infection or Disease
  申请人：Condon M. Stephen

  公开号：US20070219212A1

  公开（公告）日：2007-09-20

  The invention is directed to novel pyranoindole derivatives and analogs as well as compositions containing the same and to the use thereof for the treatment, prevention or inhibition of viral infections and associated diseases caused by the Hepatitis C virus.

  这项发明涉及新型吡喃吲哚衍生物和类似物，以及含有这些物质的组合物，以及将其用于治疗、预防或抑制由丙型肝炎病毒引起的病毒感染和相关疾病的用途。
• 2-AMINOQUINAZOLINE DERIVATIVE
  申请人：Sawa Masaaki

  公开号：US20100311965A1

  公开（公告）日：2010-12-09

  An object of the present invention is to provide compounds which are useful as protein kinase inhibitors. Disclosed is a 2-aminoquinazoline derivative represented by the following formula (I): wherein R 1 represents a lower alkyl group which may be substituted with a halogen atom, or a halogen atom; R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted acylamino group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, or a substituted or unsubstituted lower alkylureido group; and X, Y and Z each independently represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a carboxyl group, a lower alkoxycarbonyl group, a cyano group, a carbamoyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted lower alkoxycarbonylamino group, a substituted or unsubstituted lower alkylaminocarbonyl group, a lower alkylsulfonylamino group, a substituted or unsubstituted lower alkylureido group, or a substituted or unsubstituted acylamino group, or X and Y may be combined to form a 5- to 6-membered ring forming a bicyclic fused ring, wherein the 5- to 6-membered ring may optionally have a substituent, provided that when X and Y are not combined to form a fused ring, R 2 represents a hydrogen atom and, when X and Y are combined to form a fused ring, a saturated or unsaturated, bicyclic alicyclic or heterocyclic fused ring can be formed.

  本发明的目的是提供可用作蛋白激酶抑制剂的化合物。公开的是一种由以下式（I）表示的2-氨基喹唑啉衍生物：其中R1表示可以被卤素原子取代的低级烷基基团或卤素原子；R2表示氢原子、取代或未取代的低级烷基基团、卤素原子、羟基、取代或未取代的低级烷氧基团、取代或未取代的氨基、取代或未取代的酰胺基、羧基、低级烷氧羰基基团、氨基甲酰基基团、氰基、取代或未取代的低级烷氧羰胺基团、取代或未取代的低级烷基氨基甲酰基团、低级烷基磺酰氨基基团、取代或未取代的低级烷基脲基基团或取代或未取代的酰胺基；X、Y和Z各自独立地表示氢原子、取代或未取代的低级烷基基团、卤素原子、羟基、羧基、低级烷氧羰基基团、氰基、氨基甲酰基基团、取代或未取代的低级烷氧基团、取代或未取代的低级烷氧羰胺基团、取代或未取代的低级烷基氨基甲酰基团、低级烷基磺酰氨基基团、取代或未取代的低级烷基脲基基团或取代或未取代的酰胺基，或X和Y可以结合形成一个5-到6-成员环形成一个双环融合环，其中5-到6-成员环可以选择地具有取代基，但是当X和Y没有结合形成融合环时，R2表示氢原子；当X和Y结合形成融合环时，可以形成饱和或不饱和、双环融合脂环或杂环融合环。
• EP2226315
  申请人：——

  公开号：——

  公开（公告）日：——
• PYRANOINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION OR DISEASE
  申请人：Viropharma Incorporated

  公开号：EP1765330A2

  公开（公告）日：2007-03-28
• EP1765330A4
  申请人：——

  公开号：EP1765330A4

  公开（公告）日：2007-10-17